As Kymriah Fetches Highest List Price, Policymakers Talk over Difficulty in Cell Therapy Pricing

Kenporen Director Shoji Kono (right) As Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) received the highest NHI price of nearly 33.5 million yen, policymakers discussed difficulties surrounding the pricing of cell and gene therapies under the current rules at a...read more